LIGHTWEIGHT CRYPTOGRAPHY METHOD IN THE INTERNET OF THINGS USING ELLIPTIC CURVE AND CROW SEARCH ALGORITHM

The Internet of Things (IoT) as an important technology consists of a heterogeneous and huge number of devices that generates an enormous amount of data in various applications. However, generating and transmitting huge amount of data in the IoT makes it crucial to implement a secure and safe data transmission scheme. Cryptography methods can secure the confidentiality, data integrity, access control, and authentication. Due to constrained resources in IoT devices, providing classical cryptography schemes isn’t efficient for IoT applications, so a lightweight cryptography scheme is one of the most important solutions to overcome security challenges in IoT. In this paper, a new security scheme called ECCCSASHA256 based on Elliptic Curve Cryptography (ECC) and Secure Hash Algorithm (SHA-256) using Crow Search Algorithm (CSA) has been proposed for secure data transmission in IoT devices. The ECCCSASHA256 model uses the CSA for generating a private key to encode the elliptic curve. Furthermore, the proposed scheme uses SHA-256 model for hashing the incoming encoded data using ECC. The simulation results indicate that the average throughput of the proposed model was about 8.22% and 8.97% higher in encryption and 8.72% and 9.81% higher in decryption compared to 3DES&ECC&SHA-256 and RC4&ECC&SHA-256, respectively

Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and risk of atherosclerotic cardiovascular disease. Apart from hyperglycemia, dyslipidemia and HDL dysfunction are known risk factors for neuropa-thy in people with obesity and diabetes. Although there are case reports of statin-induced neuropathy, ad hoc analyses of clinical trials and observational studies have shown that statins may improve peripheral neuropathy. However, large randomized controlled trials and meta -analyses of cardiovascular outcome trials with statins and other lipid-lowering drugs have not reported on neuropathy outcomes. Because neuropathy was not a prespecified outcome in major cardiovascular trials, one cannot conclude whether statins or other lipid -lowering therapies increase or decrease the risk of neuropathy. The aim of this review was to assess if statins have beneficial or detrimental effects on neuropathy and whether there is a need for large well-powered interventional studies using objective neuropathy end points. (Clin Ther. 2022;44:1012- (c) 2022 Published Elsevier Inc